Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ECT204 |
Trade Name | |
Synonyms | ECT-204|ECT 204 |
Drug Descriptions |
ECT204 are autologous human T-lymphocytes engineered to express an antibody-based antigen-binding domain targeting GPC3 and an effector-binding domain, which potentially lead to cytotoxic T-lymphocyte (CTL)-dependent killing of GPC3 expressing tumor cells (NCI Drug Dictionary). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C180673 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ECT204 | ECT204 | 0 | 1 |